Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis

  • Matzno S
  • Tazuya-Murayama K
  • Tanaka H
  • et al.
29Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Rhabdomyolysis is a severe adverse effect of hypolipidaemic agents such as statins and fibrates. We evaluated this muscular cytotoxicity with an in-vitro culture system. Cellular apoptosis was determined using phase-contrast and fluorescein microscopic observation with Hoechst 33342 staining. L6 rat myoblasts were treated with various statins and bezafibrate under various conditions. With statins only, skeletal cytotoxicity was ranked as cerivastatin > fluvastatin > simvastatin > atorvastatin > pravastatin in order of decreasing potency. Combined application of fibrates enhanced ator-vastatin-induced myopathy, which causes little apoptosis alone. These results suggest that statins and fibrates synergistically aggravate rhabdomyolysis.

Cite

CITATION STYLE

APA

Matzno, S., Tazuya-Murayama, K., Tanaka, H., Yasuda, S., Mishima, M., Uchida, T., … Matsuyama, K. (2003). Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis. Journal of Pharmacy and Pharmacology, 55(6), 795–802. https://doi.org/10.1211/002235703765951401

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free